Fibromyalgia validated as a diagnosis

Read time: 2.5 minutes

Fibromyalgia has occupied an uncomfortable position in general practice for as long as it has had a name. Chronic widespread pain, fatigue and cognitive fog, disproportionately affecting women in mid-life, with nothing to find on examination and nothing to find on investigation. The result is a condition some clinicians treat as a syndrome to be managed and others quietly treat as a diagnosis of exclusion that never quite excludes anything. The largest genetic study ever run on it has now been published, and it settles at least one of the long-running arguments.

The uncertainty has had costs that show up in the notes. People with fibromyalgia accumulate referrals, repeat imaging and normal bloods, and somewhere along the way absorb the message that because nothing has been found, there is nothing there. The competing explanations have not helped. A muscle disorder points the workup one way, an autoimmune process points it another, and the overlap with depression and myalgic encephalomyelitis has left the label looking less like a diagnosis than a holding pattern.

On the genetics, fibromyalgia sits closer to post-traumatic stress disorder than to depression.

There is now a defensible answer to the question that gets asked in the room, which is whether this is real. It is, and the evidence locates it in the nervous system rather than in the tissues where the pain is felt. That reframe does clinical work as well as conversational work. If the mechanism is central rather than peripheral, further peripheral investigation is unlikely to be productive, and treatments aimed at central pain processing have a rationale behind them rather than just a track record.

The study, published in Nature Medicine, pooled genetic data from 2,563,755 people across 11 cohorts in the US, UK, Finland, Estonia, Denmark and Iceland, including 54,629 with a fibromyalgia diagnosis. It identified 26 independent genome-wide significant risk loci. Heritability was enriched exclusively within brain tissue and neural cell types, with the strongest signals in hippocampal dentate gyrus neurons and enteric neurons. There was no enrichment in muscle. The strongest single association sat within HTT, the gene implicated in Huntington's disease, carrying roughly 9% increased odds, though the variant involved is separate from the mutation that causes Huntington's. A second locus implicated GPR52, which regulates HTT levels and is already being pursued as a drug target in Huntington's disease.

The genetic correlations are arguably the more immediately useful finding. Fibromyalgia correlated strongly with post-traumatic stress disorder, low back pain and irritable bowel syndrome, moderately with depression, and shared risk loci with chronic fatigue syndrome. The PTSD figure is the striking one, close enough to the pain conditions to sit alongside them rather than below them. None of this delivers a test or a treatment yet. What it delivers is a mechanism, and a mechanism changes what a diagnosis feels like both to give and to receive. The comorbidities that once made fibromyalgia look like a diagnosis of last resort now look like part of the same picture.